Get started
AbbVie Inc.AbbVie Inc.AbbVie Inc.

AbbVie Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

ABBV trade ideas

Abbvie Inc set for revenue boost Shipments underway to China in the hope that the Coronavirus can be tackled by Abbvie's range of Antiviral drugs. Deep retrace had completed as has a bullish golden cross. The chart is not exactly bullish but fundamentals may dictate the next move. Above the 50 day moving average is a possible point of entry AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
NYSE:ABBV
by Bullishcharts
ABBVIE bullish on new DealZURICH (Reuters) - U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators. AbbVie is swallowing Allergan to give it control of the lucrative wrinkle treatment Botox and to diversify a portfolio heavily dependent on its $19-billion-per-year arthritis drug Humira, the world's best-selling medicine that is advancing toward U.S. patent expiration. Swiss food group Nestle bulked up its medical nutrition business with Allergan's Zenpep, a product with 2018 sales of $237 million which treats people whose pancreases do not provide enough enzymes to digest fats, proteins and sugars. Nestle did not give financial details, but analysts from Zuercher Kantonalbank estimated the takeover could have cost the Vevey, Switzerland-based company more than $1 billion. Meanwhile, AstraZeneca is regaining rights to brazikumab, Allergan's experimental drug against Crohn's Disease and ulcerative colitis. The European Commission said this month the immunology medicine must be divested because of the risk its development would be halted after AbbVie's takeover because of competing medicines. "These definitive agreements represent significant progress toward the completion of our acquisition of Allergan," Richard Gonzalez, AbbVie's chairman and chief executive, said. With regulators wary of the deal's anti-competitive potential, rivals are getting a chance to stock their own product shelves. Nestle Chief Executive Mark Schneider, who also gets Allergan's Viokace, another pancreatic enzyme product, in Monday's deal, is bulking up on nutrition products that combine properties of medicine and food as the Swiss company expands in areas where growth may outpace its mainstream food business. "This is a significant opportunity for our business in the United States," Greg Behar, head of Nestle Health Science, said in a statement. AstraZeneca's pact for brazikumab marks a return of the inflammation medicine to the British drugmaker's portfolio. In 2016, Astra had struck a licensing deal with Allergan worth up to $1.5 billion for the medicine. With its return to AstraZeneca, Allergan has agreed to fund development costs for brazikumab in Crohn's disease and ulcerative colitis, including the creation of a companion diagnostic, AstraZeneca said in a separate statement. "This agreement creates an opportunity for us to complete the full development program and bring this potential new treatment option to patients as quickly as possible," Mene Pangalos, Astra's biopharmaceuticals research head. Even if Allergan must foot the development bill, analysts appeared underwhelmed, in part because AbbVie's Skyrizi, or risankizumab, a similar medicine, has a head start. "This could be another autoimmune product to add to Astra's portfolio, although it will be somewhat late to the market," Liberum's Alistair Campbell wrote in a note to investors.
NYSE:ABBV
by RedHotStocks
Buy and sell opportunityChart and trend analysis: Monthly timeframe - down Weekly timeframe - down Daily timeframe - up Hourly timeframe - up Trade action: Long-term opportunity - SELL, then BUY Short-term opportunity - BUY until price reaches the sell zone Important points: 1] Both, buy or sell zones have 2 price levels, color-coded for your understanding: Green (enter a trade), Red (exit the trade or stop-loss) 2] Your choice of buying or selling depends on your timeframe (long term wealth investor vs. short term income trader). 3] Follow our T4 strategy when the price reaches the zone: wait for a bullish and bearish reversal in buy and sell zones respectively. 4] Risk management strategies are critical in any trading or investing activity such as position size (how much to invest) or stop-loss (knowing when to exit with an acceptable, predefined, minimal loss). Visit us to learn more: www.usstockadvisor.com
NYSE:ABBVEducation
by usstockadvisor
ABBV remains a strong investment even after its recent runAbbvie has been surging lately after a bullish trend line break, but it remains undervalued at the current price. The analyst summary score for Abbvie is 9.6/10, and the average analyst price target is $92 per share. Personally, I think Abbvie's strong earnings forecast and 5.5% dividend yield justifies $100 per share. Call volume in Abbvie is very bullish today after its cancer drug Imbruvica beat a rival cancer drug in a clinical trial.
NYSE:ABBVLong
by ChristopherCarrollSmith
ABBV looking to continue it's upside crawlIn full disclosure I have an open position in this name and will look to add another position on break over the 200 MA. As you can see I've drawn in a pennant that just broke to the upside today, 10/17. I'd keep a tight stop on a new entry at $72.80 at first, then after it's a few $$ in profit I'd trail it with the 200 MA. I'll treat any addition to my position as a completely new trade. A word of additional caution, there was a gap not yet filled back in June. This could act as additional resistance. I have a core position for the dividend which at this point is worth a 5.7% yield (my cost basis in the core position is much lower so my yield is about 6.5%). I'll wait for this stock to recover into the $100 range. (Too much info, LOL) Target on this trade $82.00. Ideas, not trading advice.
NYSE:ABBVLong
by jaxdog